Brief Title
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients
Official Title
Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients : What About Their Consequences ?
Brief Summary
The diagnosis and the follow-up of acromegalic patients are based on the mesurement of Growth hormone (GH) and IGF1 rates. However, the literature described some cases of patient for whom the investigators observed a discrepancy between GH and IGF1 rates. Since the acromegaly is a rare disease and this phenomenon concerns about 30% of these patients, there is a lack of investigations about consequences that this discordance may induces. In this study, the investigators aimed at assessing if patients with discordance between GH and IGF1 rates present a different risk of recurrence and complications related to acromegaly, from patients with concordant results.
Study Type
Observational
Primary Outcome
Occurrence of complications and/or recidivism related to acromegaly
Secondary Outcome
Disease's specificity
Condition
Acromegaly
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
250
Start Date
January 1, 2010
Completion Date
December 1, 2022
Primary Completion Date
April 1, 2022
Eligibility Criteria
Inclusion criteria: - Acromegaly followed up in one of the center (Montpellier, Nimes or Béziers hospital, independent endocrinologist) between 2010 and 2021 - Age over 18 years old - Measurement of GH and IGF1 rates at the last visit control available Exclusion criteria: - Lost to follow-up - Status about complications related to acromegaly unknown
Gender
All
Ages
18 Years - 100 Years
Accepts Healthy Volunteers
No
Contacts
Isabelle RAINGEARD, 06.71.31.76.37, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT04860037
Organization ID
RECHMPL21_0229
Responsible Party
Sponsor
Study Sponsor
University Hospital, Montpellier
Study Sponsor
Isabelle RAINGEARD, Principal Investigator, University Hospital, Montpellier
Verification Date
April 2021